Determination of linezolid in human plasma by LC-MS-MSElectronic Supplementary Information available. See http://www/rsc/org/suppdata/an/b1/b100076o/

Abstract

A rapid, sensitive and selective LC-atmospheric pressure-chemical ionization-MS-MS method for the determination of the new antimicrobial agent, linezolid, in human plasma using selected reaction monitoring (SRM) was developed. Linezolid and the internal standard were extracted from the biological samples by solid phase extraction (SPE) and analyzed on a reversed-phase Shim Pack CLC-CN, C18 column with the mobile phase of acetonitrile and 20 mM ammonium acetate solution (4 + 1 v/v). Detection was accomplished using an LCQ^TM mass spectrometer (Finnigan), which was programmed in positive MS-MS mode to permit measurement of the fragment ions of linezolid and internal standard at m/z 296.2 and 223.2, respectively. The assay run-time was less than 3.5 min. Quantitative analysis was based on peak area ratio of linezolid to the internal standard. Calibration plots were established over the concentration range of 0.1–20 μg ml⁻¹ of linezolid with the lowest detection limit of 0.05 μg ml⁻¹ using 10 μl sample volume. The SPE technique quantitatively recovered linezolid and the internal standard from the plasma samples at a percentage range of 89.1–93.7%. Determination of control samples of linezolid in plasma validated the LC-MS-MS-SRM method. Intra-assay and inter-assay precision were in the range of 5.1–11.4% relative standard deviation, whereas the intra- and inter-accuracy were in the range of 97.5–114.0% of the nominal concentrations of linezolid added. The data confirmed that the plasma samples of linezolid were stable at room temperature and when stored at −20 °C for at least 10 d. The developed LC-MS-MS-SRM method is recommended for the determination of linezolid in human plasma.